PE-conjugated Anti-CD5L antibody(DMC441); IgG1 Chimeric mAb

Cat. No. DMC100441P

PRODUCT INFORMATION

Clone ID	**Warning**: Undefined variable $hasAttributeValueDescription in **/www/wwwroot/tech.dimabio.cn/wp-content/plugins/woocommerce-print-products/public/class-woocommerce-print-products-public.php** on line **2806** DMC441
Target	CD5L
Synonyms	AIM; API6; CT-2; hAIM; PRO229; SP-ALPHA; Spalpha
Host Species	Rabbit
Description	PE-conjugated Anti-CD5L antibody(DMC441); IgG1 Chimeric mAb
Delivery	Under Development
Uniprot ID	O43866
IgG type	Rabbit/Human Fc chimeric IgG1
Clonality	Monoclonal
Reactivity	Human
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Liquid□PBS with 0.05% Proclin300, 1% BSA
Storage&Shipping	Store at 2°C-8°C for 6 months
Background	Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by macrophages in lymphoid and inflamed tissues and regulates mechanisms in inflammatory responses; such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes. Following incorporation into mature adipocytes via CD36-mediated endocytosis; associates with cytosolic FASN; inhibiting fatty acid synthase activity and leading to lipolysis; the degradation of triacylglycerols into glycerol and free fatty acids (FFA). CD5L-induced lipolysis occurs with progression of obesity: participates in obesity-associated inflammation following recruitment of inflammatory macrophages into adipose tissues; a cause of insulin resistance and obesity-related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC; the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells; where it decreases the content of polyunsaturated fatty acyls (PUFA); affecting two metabolic proteins MSMO1 and CYP51A1; which synthesize ligands of RORC; limiting RORC activity and expression of pro-inflammatory genes. Participates in obesity-associated autoimmunity via its association with IgM; interfering with the binding of IgM to Fcalpha:mu receptor and enhancing the development of long-lived plasma cells that produce high-affinity IgG autoantibodies (By similarity). Also acts as an inhibitor of apoptosis in macrophages: promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis (PubMed:24295828). Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy (PubMed:16030018; PubMed:24223991; PubMed:24583716; PubMed:25713983).
Usage	Research use only
Conjugate	PE-conjugated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scr

DIMABIO CONFIDENTIAL

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China
Telephone: +1 2409940618(USA) /+86-18062749453(China) /+86-400-006-0995(China)

Email: info@dimabio.com
Website: www.dimabio.com